Literature DB >> 22434030

Autoimmunity and Graves' disease.

R S Bahn1.   

Abstract

Current treatment options for Graves' hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22434030      PMCID： PMC3902011          DOI： 10.1038/clpt.2012.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Thyroid       Date:  2011-04-21       Impact factor: 6.568

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

4.  A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor.

Authors:  Susanne Neumann; Elena Eliseeva; Joshua G McCoy; Giorgio Napolitano; Cesidio Giuliani; Fabrizio Monaco; Wenwei Huang; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2010-12-01       Impact factor: 5.958

5.  A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.

Authors:  Jane Sanders; Michele Evans; Corrado Betterle; Paul Sanders; Anshu Bhardwaja; Stuart Young; Emma Roberts; Jane Wilmot; Tonya Richards; Angela Kiddie; Kasemsri Small; Hayley Platt; Sara Summerhayes; Rebecca Harris; Magnus Reeve; Graziella Coco; Renato Zanchetta; Shu Chen; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Thyroid       Date:  2008-07       Impact factor: 6.568
  5 in total
  15 in total

1.  Emerging pharmacotherapy for treatment of Graves' disease.

Authors:  Rebecca S Bahn
Journal:  Expert Rev Clin Pharmacol       Date:  2012-11       Impact factor: 5.045

Review 2.  Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Yasmin Shayesteh; Walter M Jay
Journal:  Neuroophthalmology       Date:  2015-06-17

3.  A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Authors:  Adina F Turcu; Seema Kumar; Susanne Neumann; Michael Coenen; Seethalakshmi Iyer; Pamela Chiriboga; Marvin C Gershengorn; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

4.  Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy.

Authors:  Kai-Chun Cheng; Han-Hsiang Huang; Chun-Tzu Hung; Cheng-Chi Chen; Wen-Chuan Wu; Jau-Ling Suen; Kuo-Jen Chen; Yu-Jen Wu; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-28       Impact factor: 3.117

Review 5.  Novel insights on thyroid-stimulating hormone receptor signal transduction.

Authors:  Gunnar Kleinau; Susanne Neumann; Annette Grüters; Heiko Krude; Heike Biebermann
Journal:  Endocr Rev       Date:  2013-05-03       Impact factor: 19.871

6.  The influence of orbital decompression on objective nasal function in patients with graves' orbitopathy.

Authors:  Kerstin Stähr; Laura Holtmann; Anke Schlüter; Friederike Kaster; Michael Oeverhaus; Stephan Lang; Anja Eckstein; Stefan Mattheis
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-30       Impact factor: 2.503

7.  Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.

Authors:  Diego Strianese; Francesca Rossi
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

8.  Graves Disease Is Associated With Endometriosis: A 3-Year Population-Based Cross-Sectional Study.

Authors:  Jin-Sung Yuk; Eun-Ju Park; Yong-Soo Seo; Hee Jin Kim; Seon-Young Kwon; Won I Park
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Molecular sampling of the allosteric binding pocket of the TSH receptor provides discriminative pharmacophores for antagonist and agonists.

Authors:  Inna Hoyer; Ann-Karin Haas; Annika Kreuchwig; Ralf Schülein; Gerd Krause
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

Review 10.  Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors.

Authors:  Selvaraj G Nataraja; Henry N Yu; Stephen S Palmer
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-14       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.